Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities

Mingqiang Ren, H. Qin, R. Ren, John Kenneth Cowell

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Myeloid and lymphoid malignancies associated with fibroblast growth factor receptor-1 (FGFR1) abnormalities are characterized by constitutively activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for stem cell leukemia/lymphoma (SCLL). Ponatinib (AP24534), which potently inhibits native and mutant BCR-ABL, also targets the FGFR family. Using murine BaF3 cells, stably transformed with six different FGFR1 fusion genes, as well as human KG1 cells expressing activated chimeric FGFR1 and five newly established murine SCLL cell lines, we show that ponatinib (<50 nM) can effectively inhibit phosphoactivation of the fusion kinases and their downstream effectors, such as PLCγ, Stat5 and Src. Ponatinib also significantly extended survival of mice transplanted with different SCLL cell lines. Ponatinib administered at 30 mg/kg daily also significantly delayed, or even prevented, tumorigenesis of KG1 cells in xenotransplanted mice. Furthermore, we demonstrate that ponatinib specifically inhibits cell growth and clonogenicity of normal human CD34+ progenitor cells transformed by chimeric FGFR1 fusion kinases. Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalLeukemia
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Stem Cells
Lymphoma
Leukemia
Phosphotransferases
Neoplasms
Molecular Targeted Therapy
Cell Line
Gene Fusion
ponatinib
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Carcinogenesis
Growth

Keywords

  • FGFR1
  • myeloproliferative disease
  • ponatinib
  • preclinical trial

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. / Ren, Mingqiang; Qin, H.; Ren, R.; Cowell, John Kenneth.

In: Leukemia, Vol. 27, No. 1, 01.01.2013, p. 32-40.

Research output: Contribution to journalArticle

@article{099d7c3009f447d2a55e3c1fb11f7aa0,
title = "Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities",
abstract = "Myeloid and lymphoid malignancies associated with fibroblast growth factor receptor-1 (FGFR1) abnormalities are characterized by constitutively activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for stem cell leukemia/lymphoma (SCLL). Ponatinib (AP24534), which potently inhibits native and mutant BCR-ABL, also targets the FGFR family. Using murine BaF3 cells, stably transformed with six different FGFR1 fusion genes, as well as human KG1 cells expressing activated chimeric FGFR1 and five newly established murine SCLL cell lines, we show that ponatinib (<50 nM) can effectively inhibit phosphoactivation of the fusion kinases and their downstream effectors, such as PLCγ, Stat5 and Src. Ponatinib also significantly extended survival of mice transplanted with different SCLL cell lines. Ponatinib administered at 30 mg/kg daily also significantly delayed, or even prevented, tumorigenesis of KG1 cells in xenotransplanted mice. Furthermore, we demonstrate that ponatinib specifically inhibits cell growth and clonogenicity of normal human CD34+ progenitor cells transformed by chimeric FGFR1 fusion kinases. Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.",
keywords = "FGFR1, myeloproliferative disease, ponatinib, preclinical trial",
author = "Mingqiang Ren and H. Qin and R. Ren and Cowell, {John Kenneth}",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/leu.2012.188",
language = "English (US)",
volume = "27",
pages = "32--40",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities

AU - Ren, Mingqiang

AU - Qin, H.

AU - Ren, R.

AU - Cowell, John Kenneth

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Myeloid and lymphoid malignancies associated with fibroblast growth factor receptor-1 (FGFR1) abnormalities are characterized by constitutively activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for stem cell leukemia/lymphoma (SCLL). Ponatinib (AP24534), which potently inhibits native and mutant BCR-ABL, also targets the FGFR family. Using murine BaF3 cells, stably transformed with six different FGFR1 fusion genes, as well as human KG1 cells expressing activated chimeric FGFR1 and five newly established murine SCLL cell lines, we show that ponatinib (<50 nM) can effectively inhibit phosphoactivation of the fusion kinases and their downstream effectors, such as PLCγ, Stat5 and Src. Ponatinib also significantly extended survival of mice transplanted with different SCLL cell lines. Ponatinib administered at 30 mg/kg daily also significantly delayed, or even prevented, tumorigenesis of KG1 cells in xenotransplanted mice. Furthermore, we demonstrate that ponatinib specifically inhibits cell growth and clonogenicity of normal human CD34+ progenitor cells transformed by chimeric FGFR1 fusion kinases. Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.

AB - Myeloid and lymphoid malignancies associated with fibroblast growth factor receptor-1 (FGFR1) abnormalities are characterized by constitutively activated FGFR1 kinase and rapid transformation to acute myeloid leukemia and lymphoblastic lymphoma. Molecular targeted therapies have not been widely used for stem cell leukemia/lymphoma (SCLL). Ponatinib (AP24534), which potently inhibits native and mutant BCR-ABL, also targets the FGFR family. Using murine BaF3 cells, stably transformed with six different FGFR1 fusion genes, as well as human KG1 cells expressing activated chimeric FGFR1 and five newly established murine SCLL cell lines, we show that ponatinib (<50 nM) can effectively inhibit phosphoactivation of the fusion kinases and their downstream effectors, such as PLCγ, Stat5 and Src. Ponatinib also significantly extended survival of mice transplanted with different SCLL cell lines. Ponatinib administered at 30 mg/kg daily also significantly delayed, or even prevented, tumorigenesis of KG1 cells in xenotransplanted mice. Furthermore, we demonstrate that ponatinib specifically inhibits cell growth and clonogenicity of normal human CD34+ progenitor cells transformed by chimeric FGFR1 fusion kinases. Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.

KW - FGFR1

KW - myeloproliferative disease

KW - ponatinib

KW - preclinical trial

UR - http://www.scopus.com/inward/record.url?scp=84873570654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873570654&partnerID=8YFLogxK

U2 - 10.1038/leu.2012.188

DO - 10.1038/leu.2012.188

M3 - Article

VL - 27

SP - 32

EP - 40

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -